[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Clatterbridge Cancer Centre NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,69,92,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650482","her2-cns-surveillance-100650482",false,"NCT07748598","HER2+ CNS Surveillance","HER2-CNS SURVEILLANCE: A Study of the Feasibility of Randomising Women and Men With HER2 Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus no Surveillance","HER2+ CNS","Inclusion Criteria Age 16 years or older. Male or female. Histologically or cytologically confirmed HER2-positive breast cancer with evidence of metastatic breast cancer.\n\nEstrogen receptor (ER) positive or negative disease. Visceral disease present. Receiving active HER2-directed therapy. ECOG Performance Status 0-2. Life expectancy greater than 6 months. Written informed consent and ability to comply with study procedures and follow-up.\n\nExclusion Criteria History of brain metastases. History or evidence of leptomeningeal carcinomatosis. Symptoms suggestive of brain metastases. Inability to tolerate or undergo MRI scans. Bone-only metastatic disease. Significant medical condition or laboratory finding that would make study participation undesirable.\n\nInability to provide informed consent.","ALL","16 Years",{"count":20,"type":21},69,"ESTIMATED","INTERVENTIONAL",[24],"NA","A multi-centre, randomised study, to determine the feasibility of recruiting men and women with metastatic HER2 positive breast cancer to a study with a baseline MRI scan followed by randomising to surveillance by two further six-monthly MRI scans versus no further surveillance of the brain. Qualitative research (focus groups and\u002For interviews) and monitoring of approach and consent with SEAR framework will be embedded within the trial to achieve the primary endpoint and explore challenges with study implementation and delivery.",[27,28,29],"Her 2 Positive Breast Cancer","Cancer","CNS","RECRUITING","2026-08-04",{"date":33,"type":34},"2026-08-05","ACTUAL",{"date":36,"type":34},"2025-10-03",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"The Clatterbridge Cancer Centre NHS Foundation Trust","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100649859","flow-on-fnacore-project--faster-diagnosis-for-lymphoma-utilising-flow-cytometry-on-fna-samples-of-lymph-nodes-to-diagnose-lymphoma-in-hours-not-days-100649859","NCT07739849","Flow on FNA\u002FCore Project- Faster Diagnosis for Lymphoma: Utilising Flow Cytometry on FNA Samples of Lymph Nodes to Diagnose Lymphoma in Hours, Not Days.","Short Title Flow on FNA\u002FCore Project Full Title Faster Diagnosis for Lymphoma: Utilising Flow Cytometry on FNA Samples of Lymph Nodes to Diagnose Lymphoma in Hours, Not Days","Flow on FNA","Inclusion criteria\n\n\\- Patient on a diagnostic pathway for cancer due to lymphadenopathy, with lymphoma one of the differentials\n\nExclusion criteria\n\n* Patients unable to consent\n* Patients aged \\\u003C18","18 Years",{"count":53,"type":21},200,[24],"The current typical pathway for patients with enlarged lymph glands is to undergo a fine needle aspirate (FNA) under ultrasound, which is then reported by histopathology, typically within one week. If it's suspicious for a lymphoma, when the patient returns to clinic, a core\u002F excision biopsy is arranged. The current waiting time for a biopsy, either surgically or via radiology, is 2-4 weeks. After the biopsy has been performed, the HODS (Haemato-Oncology Diagnostic Service) turn-around time for lymph node biopsy is 2 - 3 weeks (urgent, or routine samples, according to key performance metrics). It is therefore challenging to achieve a 28-day faster diagnosis for lymphoma patients.\n\nThe purpose of this project is to perform flow cytometry for immunophenotyping on FNA samples to rapidly screen and potentially identify patients who have lymphoma.",[28,57],"Lymphoma",[59],"Flow cytometry","NOT_YET_RECRUITING","2026-07-28",{"date":63,"type":34},"2026-07-31",{"date":65,"type":21},"2026-08-01",{"date":67,"type":21},"2028-07-31",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100647772","living-without-answers---illuminate-cup-100647772","NCT07712965","Living Without Answers - ILLUMINATE CUP","Illuminating the Lived Experience: Listening, Understanding and Meaning-makIng - A Narrative Analysis of the Diagnosis, Treatment and Experience of Cancer of Unknown Primary","ILLUMINATE CUP","Inclusion Criteria:\n\n* have a confirmed diagnosis of cancer of unknown primary, or care for someone who has a diagnosis of cancer of unknown primary\n* are 18 years old and above\n* have capacity to provide informed consent\n\nExclusion Criteria:\n\n* do not have capacity to provide informed consent\n* are deemed too unwell by the clinical team to take part in the research",{"count":78,"type":21},20,"OBSERVATIONAL","This project aims to improve care, service delivery, and patient experience for people with Cancer of Unknown Primary (CUP) by addressing a critical gap in understanding the lived experiences of patients and carers. By exploring how individuals navigate diagnostic uncertainty, fragmented care pathways, and interactions with healthcare professionals, the study will identify key points of distress, unmet need, and communication breakdown.\n\nThe findings will support the development of more person-centred and compassionate care, including clearer communication, improved service coordination, and better recognition of the psychological and emotional impact of CUP. By highlighting the challenges of uncertainty and lack of diagnostic clarity, the project will inform more tailored support for both patients and carers.\n\nA unique strength of this study is the inclusion of a professional illustrator to visually capture focus group discussions, supporting the narrative inquiry approach and aiding the interpretation of shared meanings within the data. These visual summaries will enhance engagement, inclusivity, and accessibility, ensuring that complex experiences are communicated clearly to patients, carers, clinicians, and wider audiences.\n\nThrough strong PPIE involvement and accessible dissemination, patient and carer voices will directly inform service improvements and future care design.\n\nOverall, this project will help ensure CUP care is more coordinated, communicative, inclusive, and responsive to patient and carer needs, ultimately improving experience, wellbeing, and trust in healthcare services.",[28,82,83],"CUP","Cancer Unknown Primary","2026-07-13",{"date":86,"type":34},"2026-07-20",{"date":88,"type":21},"2026-09-01",{"date":90,"type":21},"2028-09-01",{"name":40,"class":41},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":42},"100619262","breaking-barriers-to-research-access-100619262","NCT07342335","Breaking Barriers to Research Access","Understanding and Breaking Barriers to Research Access for Cancer Patients","Inclusion Criteria:\n\n* Adults over 18 years. No upper age limit\n* A confirmed diagnosis of cancer\n* Patient planned to or is receiving treatment at The Clatterbridge Cancer Centre NHS Foundation Trust\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Patients with severe co-morbidities considered by the screening team to interfere with the individual's ability to complete requirements of the study or to provide informed consent.",{"count":100,"type":21},300,"There is a need to improve accessibility to research and clinical trials within the NHS. Key groups are consistently under-represented in research: those from minority ethnic backgrounds, those with lower socio-economic status and those with impaired capacity. This leads to inequality of healthcare and an inequality of patient experience. Increasing access to research would not only broaden research opportunities and bridge gaps in health equality; diverse research representation means better understanding of disease mechanisms and greater generalisability of findings across the patient population. There are well described socio-economic issues across the region that this trust serves within Cheshire and Merseyside. This brings health challenges for patients. Clatterbridge Cancer Centre is a large networked cancer centre serving Cheshire and Merseyside using a hub model. Research is a core strategic theme; it is hugely important that it is understood not only the areas and hotspots of cancer across the region, but also that patients with those cancers can access a portfolio of research that serves a distinct patient need. Currently there is a lack of such triangulated information within the Trust, which may mean that patient need remains unmet. Therefore the research is designed to understand any barriers that patients may have in accessing research, in tandem with a demographic review and mapping of patient referral and access to the current trials portfolio. This will lead to a truly patient centred approach in accessing research.",[28],[104],"Research Barriers","2026-04-13",{"date":107,"type":34},"2026-04-15",{"date":109,"type":34},"2024-11-29",{"date":111,"type":21},"2026-11-30",{"name":40,"class":41},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":42},"100618707","a-real-world-data-and-sample-compendium-of-frail-andor-multiply-treated-large-b-cell-lymphoma-100618707","NCT07335120","A Real-world Data and Sample Compendium of Frail and\u002For Multiply Treated Large B-cell Lymphoma","A reaL-world Data and Sample coMpendium of frAil aNd\u002For Multiply treAted Patients With Large B-Cell Lymphoma","ALMANAC","Inclusion Criteria:\n\n* Males and female subjects ≥16 years of age at the time of enrolment.\n* Ability to understand and sign written informed consent.\n* Previously untreated histologically proven Large B-cell non-Hodgkin's lymphoma (LBCL) according to the current World Health Organisation 2016 classification including all morphological variants.\n\nCohort A:\n\n* Large B-cell lymphomas i) Diffuse large B-cell lymphoma, NOS ii) T-cell\u002Fhistiocyte-rich large B-cell lymphoma iii) Diffuse large B-cell lymphoma\u002F high grade B-cell lymphoma with MYC and BCL2 re-arrangements. iv) High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements v) ALK-positive large B-cell lymphoma vi) Large B-cell lymphoma with IRF4 rearrangement vii) High-grade B-cell lymphoma with 11q aberrations or Burkitt-like lymphoma with 11q aberration viii) EBV-positive diffuse large B-cell lymphoma EBV-positive diffuse large B-cell lymphoma, NOS ix) Diffuse large B-cell lymphoma associated with chronic inflammation x) Fibrin-associated large B-cell lymphoma xi) Plasmablastic lymphoma xii) Primary large B-cell lymphoma of immune-privileged sites (vitro-retinal and testis but not CNS) and Intravascular large B-cell lymphoma xiii) Primary mediastinal large B-cell lymphoma xiv) Mediastinal grey zone lymphoma B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma xv) High-grade B-cell lymphoma, NOS xvi) HIV or KSHV\u002FHHV8-positive diffuse large B-cell lymphoma\n* De novo presentations of transformed indolent B-cell lymphomas.\n* LBCL patients with de novo disease unfit for full dose R-CHOP\u002FPola-R-CHP OR\n\nCohort B:\n\n* LBCL patients (as in Cohort A) with relapsed\u002Frefractory disease (including de novo transformed indolent B-cell lymphomas) following frontline (one previous line of chemo-immunotherapy) including any line CAR-T therapy.\n* Patients fulfilling the above criteria who are on other trials\u002Fstudies are eligible for recruitment.\n* Patients previously registered into Cohort A with subsequent relapsed\u002Frefractory disease. Such patients can be registered into cohort B and will be given a new study number that is linked to their study number for cohort A.\n* Data for patients commencing treatment \\\u003C6 months prior to enrolment and with ongoing follow-up can be entered retrospectively.\n\nExclusion Criteria:\n\n1. Patients treated \\>6 months prior to trial enrolment (Cohort B).\n2. Patients eligible for full dose R-CHOP\u002FPola-R-CHP (Cohort A)\n3. Patients with CNS lymphoma\n4. Lymphoid proliferations and lymphomas associated with immune suppression and dysregulation. (e.g., Post-Transplant Lymphoproliferative Disorders)","17 Years",{"count":123,"type":21},800,"LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as chemo-immunotherapy. Currently, the best results in the treatment of LBCL is with a chemo-immunotherapy combination called R-CHOP or Pola-R-CHP. Full doses of treatment are not suitable for elderly or frail patients due to potential to cause side effects and heart problems. Such patients either receive a reduced dose called mini-R-CHOP or receive alternatives (e.g. R-GCVP or R-CEOP). Additionally, some patients treated with R-CHOP or Pola-R-CHP may not respond or may respond initially before relapsing. For these patients, treatment is not standardised, and practice varies between hospitals. ALMANAC aims to collect data about the management and outcomes of patients with LBCL who are unsuitable for standard treatments because they are not well enough to tolerate the side effects or because they have not responded or relapsed following initial treatment. In doing so, it will guide research into LBCL leading to a better understanding of this condition and better outcomes.",[126],"DLBCL","2026-01-05",{"date":129,"type":34},"2026-01-12",{"date":131,"type":34},"2024-10-30",{"date":133,"type":21},"2028-10-30",{"name":40,"class":41},""]